Adimmune Corporation manufactures and sells human vaccines in Taiwan. More Details
Flawless balance sheet and overvalued.
Share Price & News
How has Adimmune's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4142 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 4142's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 4142 exceeded the TW Biotechs industry which returned 21.7% over the past year.
Return vs Market: 4142 exceeded the TW Market which returned 28.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Adimmune's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StIntroducing Adimmune (TPE:4142), The Stock That Zoomed 158% In The Last Three Years
2 months ago | Simply Wall StIs Adimmune (TPE:4142) Using Too Much Debt?
3 months ago | Simply Wall StShareholders Are Thrilled That The Adimmune (TPE:4142) Share Price Increased 262%
Is Adimmune undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 4142's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 4142's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 4142 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.
PE vs Market: 4142 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4142's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4142 is good value based on its PB Ratio (4.4x) compared to the TW Biotechs industry average (4.8x).
How is Adimmune forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Adimmune has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Adimmune's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Adimmune performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4142 is currently unprofitable.
Growing Profit Margin: 4142 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 4142 is unprofitable, but has reduced losses over the past 5 years at a rate of 19.7% per year.
Accelerating Growth: Unable to compare 4142's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4142 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).
Return on Equity
High ROE: 4142 has a negative Return on Equity (-1.16%), as it is currently unprofitable.
How is Adimmune's financial position?
Financial Position Analysis
Short Term Liabilities: 4142's short term assets (NT$3.6B) exceed its short term liabilities (NT$404.8M).
Long Term Liabilities: 4142's short term assets (NT$3.6B) exceed its long term liabilities (NT$1.0B).
Debt to Equity History and Analysis
Debt Level: 4142's debt to equity ratio (20.8%) is considered satisfactory.
Reducing Debt: 4142's debt to equity ratio has reduced from 37.5% to 20.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4142 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 4142 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 11.2% each year
What is Adimmune current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 4142's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 4142's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 4142's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 4142's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 4142's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Qi Xian Zhan
Qi Xian Zhan has been Chief Executive Officer of Adimmune Corporation since July 01, 2008 and serves as its Chairman of the Board of Directors. Qi Xian Zhan served as President at Chi Mei Hospital. Qi Xian...
|Chairman of the Board of Directors and Chief Executive Officer||12.5yrs||no data||0.79% |
|Chief Financial Officer and Director||no data||no data||no data|
|Chief Operating Officer||16.17yrs||no data||0.000020% |
|Administrative Center Director||9.5yrs||no data||no data|
|Legal Counsel||8.83yrs||no data||no data|
|Deputy General Manager||no data||no data||0.14% |
Experienced Management: 4142's management team is seasoned and experienced (11.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.4%.
Adimmune Corporation's company bio, employee growth, exchange listings and data sources
- Name: Adimmune Corporation
- Ticker: 4142
- Exchange: TSEC
- Founded: 1965
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$22.463b
- Shares outstanding: 429.51m
- Website: https://www.adimmune.com.tw
Number of Employees
- Adimmune Corporation
- No. 389, Xiangshun Rd
- Sec. 2
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|4142||TSEC (Taiwan Stock Exchange)||Yes||Common Stock||TW||TWD||Sep 2010|
Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, an influenza vaccine; tetanus toxoid alum precipitated products used for prevention of tetanus after injury; Japan...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/21 08:39|
|End of Day Share Price||2021/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.